drugset / Trial / NCT00161044
An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if galantamine is an effective agent for the treatment of the cognitive abnormalities, negative symptoms, and /or behavioral impairments seen in schizophrenia.
Timeline
- Start
- 2004-09
- Primary completion
- —
- Completion
- 2005-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Galantamine | Small molecule | 16 mg | — |
| Subject | Galantamine | Small molecule | 24 mg | — |